ArticleHuman vaccines & immunotherapeutics2022

Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial".

Sanjay Hadigal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.